Altogether, 26 funds focused on pharma and healthcare collectively manage Rs 30,306 crore. Some of them offer exposure to ...

Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug ...

Torrent Group was actively pursuing the acquisition of Cipla and JB Chemicals and Pharmaceuticals but ultimately withdrew due to high valuations demanded by the sellers ...

Ever since the FDA rejected zuranolone in major depressive disorder last year, brai | In the wake of a recent round of layoffs, the company this week revealed that it’s discontinuing a commercial ...

AnaptysBio (NASDAQ:ANAB), which is advancing an arthritis therapy similar to Eli Lilly's (NYSE:LLY) PD-1 agonist peresolimab, ...

The business reported a 13% growth in India revenues to ₹1,632 Crore, driven by outperformance in focus therapies.

Donald Trump and Robert F. Kennedy Jr.’s recent vow to tackle public health issues together signals a shift in Republican priorities.

Telix Pharmaceuticals leverages a novel theranostic approach, offering a unique risk-reward model in the challenging biotech ...

When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 819% — a market-crushing outperformance compared to 170% for the S&P 500.* They just ...

Typically, if it’s a planned handover, the CEO starts in six months to a year of being announced. Investors and employees ...

OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the ...

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billi | GSK has stopped development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 ...